THE US Food and Drug
Administration has created a storm
of indignation among biologic
(large molecule) therapy originator
companies by announcing that it
will allow biosimilar labels to rely
on reference drug data.
The regulatory authority
organisation made the controversial
call yesterday as part of its release
of biosimilar labelling guidelines.
Settling details of drug labelling is
an extensive and expensive process
for originator companies.The above article was sent to subscribers in Pharmacy Daily's issue from 01 Apr 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 01 Apr 16
THE stark health inequalities between Australians living in regional and metro areas have been highlighted in a new report from The Royal Flying Doctor Service (RFDS).
AN “AI explosion” is sweeping Australia’s healthcare sector, signalling the arrival of an “extraordinary era of medicine”, according to a new report from CSIRO.
THE Australian and New Zealand College of Advanced Pharmacy (ANZCAP) has celebrated the 1,000th pharmacist to complete its pharmacy recognition program (PD 24 Nov 2023).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.